Physician profile
Jonathan White
NPI 1073522132
$4,345.33
in general payments reported to CMS, 2019-2025
17 companies · $31.70 in 2025
The $31.70 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,754 · 2020: $559 · 2025: $31.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $2,969.10 | 2019-2020 | |
| Astellas Pharma US INC | $391.35 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $168.50 | 2019-2020 | |
| Allergan, INC. | $139.93 | 2019-2020 | |
| Antares Pharma, INC. | $95.56 | 2019-2020 | |
| Abbvie INC. | $94.49 | 2019 | |
| Boston Scientific Corporation | $90.00 | 2019-2025 | Accolade Sr |
| Bayer Healthcare Pharmaceuticals INC. | $87.86 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $81.26 | 2019 | |
| Janssen Biotech, INC. | $64.64 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $34.77 | 2019-2020 | |
| C. R. Bard, INC. & Subsidiaries | $28.40 | 2019 | |
| Ferring Pharmaceuticals INC. | $26.67 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $23.80 | 2019 | |
| Corcept Therapeutics | $19.49 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $16.38 | 2020 | |
| Blue Earth Diagnostics | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.